The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 559-565

  Siu, Lillian L ^a   Banerjee, Diponkar ^a   Khurana, Reena J ^a   Pan, Xia ^b   Pflueger, Rafael ^b   Tannock, Ian F ^a   Moore, Malcolm J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; METALLOTHIONEIN; METHOTREXATE; PROTEIN P53; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; AUTOANTIGENS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; METALLOTHIONEIN; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0031924088     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-28, 1997.
2. National Cancer Institute of Canada. Canadian Cancer Statistics 1997. Toronto, Canada: National Cancer Institute of Canada, 1997.
3. Tannock, I. F. The current status of adjuvant chemotherapy for bladder cancer. Semin. Urol., 8: 291-297, 1990.
4. Sternberg, C. N. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin. Oncol., 23: 621-632, 1996.
5. Loehrer, P. J., Sr., Einhorn, L. H., Elson, P. J., Crawford, D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., Lowy, B. A., Blumenstein, B., and Trump, D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol., 10: 1066-1073, 1992.
6. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
7. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
8. Stemberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Geller, N., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Bander, N., Weiselberg, L., Rosado, K., Smart, P., Liu, S., Tenenberg, D., Fair, W. R., and Whitmore, W. F., Jr. Methotrexate, vinblastine, doxorubicin and cisplatinum for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer (Phila.), 64: 2448-2458, 1989.
9. Harker, W., Meyers, F. J., Freiha, F. S., Palmer, J. M., Shortliffe, L. D., Hannigan, J. F., McWhirter, K. M., and Torti. F. M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J. Clin. Oncol., 3: 1463-1470, 1985.
10. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
11. Mostofi, F. K. Histological typing of urinary bladder tumors. In: International Histological Classification of Tumors, No. 10. Geneva: WHO, 1973.
12. Esrig, D., Spruck, C. H., III, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S-C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
13. Fienberg, S. E. The Analysis of Cross-Classified Categorical Data, pp. 9-86. Cambridge, MA: MIT Press, 1977.
14. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
15. Tannock, I. F. Cell proliferation. In: I. F. Tannock and R. P. Hill (eds.), The Basic Science of Oncology, pp. 154-177. New York: McGraw-Hill, Inc., 1992.
16. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
17. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., and Vogelstein, B. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.
18. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
19. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half life. Mol. Cell. Biol., 8: 531-539, 1988.
20. Yoshimura, I., Kudoh, J., Saito, S., Tazaki, H., and Shimizu, N. p53 gene mutation in recurrent superficial bladder cancer. J. Urol., 153: 1711-1715, 1995.
21. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
22. Thomas, D. J., Robinson, M. C., Charlton, R., Wilkinson, S., Shenton, B. K., and Neal, D. E. p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br. J. Urol., 73: 533-537, 1994.
23. Gardiner, R. A., Walsh, M. D., Alien, V., Rahman, S., Samaratunga, M. L. T. H., Seymour, G. J., and Lavin, M. F. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumor progression. Br. J. Urol., 73: 526-532, 1994.
24. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z-F., Sheinfeld, J., Fair, W. R., Herr, H. W., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
25. Nakopoulou, L., Constantinides, C., Papandropoulos, J., Theodoropoulos, G., Tzonou, A., Giannopoulos, A., Zervas, A., and Dimopoulos, C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology, 46: 334-340, 1995.
26. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z-F., Schultz, P. K., Cordon-Cardo, C., and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13: 1384-1390, 1995.
27. Soini, Y., Turpeenniemi-Hujanen, T., Kamel, D., Autio-Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Paakko, P., and Vahakangas, K. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer, 68: 1029-1035, 1993.
28. Lipponen, P. K. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
29. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z-F., Rosai, J., Reuter, V. E., and Pellicer, A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347-353, 1994.
30. Hamer, D. H. Metallothionein. Annu. Rev. Biochem., 55: 913-951. 1986.
31. Kagi, J. H. R., and Kojima, Y. (eds.). Metallothionein. II. Proceedings of the Second International Meeting on Metallothioneins and Other Low Molecular Weight, Metal Binding Proteins. Basel: Verlag, 1987.
32. Bahnson, R. R., Becich, M., Ernstoff, M. S., Sandlow, J., Cohen, M. B., and Williams, R. D. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J. Urol., 152: 2272-2275, 1994.
33. Theyer, G., and Hamilton, G. Role of multidrug resistance in tumors of the genitourinary tract. Urology, 44: 942-950, 1994.
34. Naito, S., Sakamoto, N., Kotoh, S., Goto, K., Matsumoto, T., and Kumazawa, J. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur. Urol., 22: 158-162, 1992.
35. Petrylak, D. P., Scher, H. I., Reuter, V., O'Brien, J. P., and Cordon-Cardo, C. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann. Oncol., 5: 835-840, 1994.
36. Sandlow, J., Cohen, M. B., Robinson, R. A., Dreicer, R., and Williams, R. D. DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. Urology, 43: 787-791, 1994.
37. Park, J., Shinohara, N., Liebert, M., Noto, L., Flint, A., and Grossman, H. B. P-glycoprotein expression in bladder cancer. J. Urol., 151: 43-46, 1994.
38. Bush, C., Price, P., Norton, J., Parkins, C. S., Bailey, M. J., Boyd, J., Jones, C. R., A'Hern, R. P., and Horwich, A. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br. J. Cancer. 64: 357-360, 1991.
39. Mulder, A. H., Van Hootegem, J. C. S. P., Sylvester, R., Ten Kate, F. J. W., Kurth, K. H., Ooms, E. C. M., and Van Der Kwast, T. H. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J. Pathol., 166: 37-43, 1992.
40. Kruger, S., and Muller, H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki-67 antigen expression with grading and staging in urinary bladder carcinomas. Br. J. Urol., 75: 480-484, 1995.